VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
SLSSELLAS Life Sciences Group, Inc.
$8.05$1.1B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSLSRevenue History

SLS logoSELLAS Life Sciences Group, Inc. (SLS) Revenue History

Annual and quarterly revenue from 2006 to present

TTM Revenue$0
YoY Growth—
Q1 2026$0
Revenue CAGR
3Y—
→
5Y—
→
10Y—
Best Fiscal Year$9.3M (2014)
Best Quarter$5.7M (Q1 2021)

SLS Revenue Over Time (2006–2025)

SLS Revenue Growth History

3 of 6 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2006—
2007—
2008—
2009—
2010—
2011—
2012—
2013+22.0%
2014+274.7%
2015-100.0%
2016—
2017—
2018—
2019—
2020—
2021+300.0%
2022-86.8%
2023-100.0%
2024—
2025—
FY2006 revenue growth
N/A
FY2007 revenue growth
N/A
FY2008 revenue growth
N/A
FY2009 revenue growth
N/A
FY2010 revenue growth
N/A
FY2011 revenue growth
N/A
FY2012 revenue growth
N/A
FY2013 revenue growth
+22.0%
FY2014 revenue growth
+274.7%
FY2015 revenue growth
-100.0%
FY2016 revenue growth
N/A
FY2017 revenue growth
N/A
FY2018 revenue growth
N/A
FY2019 revenue growth
N/A
FY2020 revenue growth
N/A
FY2021 revenue growth
+300.0%
FY2022 revenue growth
-86.8%
FY2023 revenue growth
-100.0%
FY2024 revenue growth
N/A
FY2025 revenue growth
N/A
DeclineStrong growth
Best: +300.0% (FY2021)Worst: -100.0% (FY2015)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$0—
Q4 2025$0—
Q3 2025$0—
Q2 2025$0—
Q1 2025$0—
Q4 2024$0—
Q3 2024$0—
Q2 2024$0—
Seasonal Revenue Pattern (fiscal quarters)
Q1
28%
Q2
7%
Q3
9%
Q4
55%

Multi-year avg. share of annual revenue by fiscal quarter

SLS Revenue Analysis (2006–2025)

Current Revenue & Growth

As of June 22, 2026, SELLAS Life Sciences Group, Inc. (SLS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue

Historical Growth Trajectory

SLS's historical revenue data shows various trends over time. SELLAS Life Sciences Group, Inc.'s highest annual revenue of $9.3 million was recorded in 2014.

Peer Comparison

Compared to Healthcare sector peers — including ADMA (+11.0% YoY), NKTR (-36.2% YoY), and CLDX (-89.2% YoY). Compare SLS vs ADMA →

SLS Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
SLS logoSLSCurrent$0---
ADMA logoADMA$510M+11.0%+64.6%37.5%
NKTR logoNKTR$55M-36.2%-18.4%-236.8%
CLDX logoCLDX$2M-89.2%-27.4%-19160.0%
AGEN logoAGEN$114M+24.5%+5.3%-18.0%
Best in groupLowest in group

SLS Historical Revenue Data (2006–2025)

1–15 of 20 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$-28,274,000-
2024$0-$0-$-31,513,000-
2023$0-100.0%$0-$-37,869,000-
2022$1.0M-86.8%$900K90.0%$-41,950,000-4195.0%
2021$7.6M+300.0%$7.4M97.4%$-25,294,000-332.8%
2020$1.9M-$1.9M100.0%$-16,982,000-893.8%
2019$0-$0-$-20,041,000-
2018$0-$0-$-31,589,000-
2017$0-$0-$-15,714,000-
2016$0-$-3,000-$-15,988,000-
2015$0-100.0%$-355,000-$-34,220,000-
2014$9.3M+274.7%$7.9M84.9%$-36,606,000-392.8%
2013$2.5M+22.0%$2.0M79.1%$-33,840,000-1360.7%
2012$2.0M-$-49,000-2.4%$-21,199,000-1040.2%
2011$0-$-20,787,000-$-20,787,000-
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

20+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

SLS — Frequently Asked Questions

Quick answers to the most common questions about buying SLS stock.

Is SLS's revenue growth accelerating or slowing?

SLS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is SLS's revenue history from 2006 to 2026?

SELLAS Life Sciences Group, Inc. (SLS) revenue history spans 2006 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is SLS's long-term revenue growth rate (CAGR)?

SELLAS Life Sciences Group, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SLS.

Why does SLS's quarterly revenue fluctuate?

SLS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. SELLAS Life Sciences Group, Inc.'s revenue data from 2006 to 2026 shows full historical quarterly detail on this page.

How is SLS's revenue distributed by segment?

SLS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does SLS's revenue compare to industry peers?

SELLAS Life Sciences Group, Inc. (SLS) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.